Teach a Computer to Recognize AML

Researchers have developed the first computer machine-learning model to accurately predict which patients diagnosed with acute myelogenous leukemia, or AML, will go into remission following treatment for their disease and which will relapse. The computer was trained using bone marrow data and medical histories of AML patients, as well as blood data from healthy individuals. Cases about which the computer had no information were evaluated by the algorithm by applying knowledge about similar cases in the database. The computer was then able to predict remission with 100 percent accuracy. Relapse was correctly predicted in 90 percent of relevant cases.

"It's pretty straightforward to teach a computer to recognize AML, once you develop a robust algorithm, and in previous work we did it with almost 100 percent accuracy," said Murat Dundar, senior author of the disease-progression study and associate professor of computer science in the School of Science at Indiana University-Purdue University Indianapolis. "What was challenging was to go beyond that work and teach the computer to accurately predict the direction of change in disease progression in AML patients, interpreting new data to predict the unknown: which new AML patients will go into remission and which will relapse."

"As the input, our computational system employs data from flow cytometry, a widely utilized technology that can rapidly provide detailed characteristics of single cells in samples such as blood or bone marrow," explained Bartek Rajwa, first author of the study and research assistant professor of computational biology in the Bindley Bioscience Center at Purdue University. "Traditionally, the results of flow cytometry analyses are evaluated by highly trained human experts rather than by machine-learning algorithms. But computers are often better at extracting knowledge from complex data than humans are."

Automated measurement and monitoring of response to treatment of AML are critical not only for objective evaluation of disease-status prognosis but also for timely assessment of treatment strategies, the study's authors noted. Their work creates and underlies a clinical decision support system that recognizes the presence of minute residual amounts of malignant cells of any AML type in bone marrow samples, enabling early identification of change in direction of disease progression.

"Machine learning is not about modeling data. It's about extracting knowledge from the data you have so you can build a powerful, intuitive tool that can make predictions about future data that the computer has not previously seen - the machine is learning, not memorizing - and that's what we did," said Dundar, an internationally respected machine-learning scientist who specializes in teaching computers to understand biomedical data.

The National Cancer Institute anticipated that 19,950 individuals would be diagnosed with AML in 2016 and forecast that approximately 10,430 deaths from AML would occur last year.

The study was a collaboration of IUPUI's Dundar and Purdue's Rajwa with Roswell Park Cancer Institute's Paul K. Wallace, a flow cytometry expert, and Elizabeth A. Griffiths, a physician who treats patients with AML.

This research, which has potential application to other hematological neoplasms in addition to AML, was supported by National Science Foundation grant IIS-1252648 (CAREER), by National Institute of Biomedical Imaging and Bioengineering grant 5R21EB015707 and in part by National Cancer Institute grant 5P30 CA01605. The content is solely the responsibility of the authors and does not necessarily represent the official views of NSF and NIH.

Rajwa B, Wallace PK, Griffiths EA, Dundar M.
Automated Assessment of Disease Progression in Acute Myeloid Leukemia by Probabilistic Analysis of Flow Cytometry Data. IEEE Trans Biomed Eng. 2016 Jul 13. doi: 10.1109/TBME.2016.2590950.

Most Popular Now

Which Self-Help Websites Actually Improv…

From depression to weight loss, insomnia to cutting back on alcohol or cigarettes, the Internet teems with sites that promise to help people improve their health. Which of these really...

Read more

AbedGraham and Highland Marketing Partne…

Global efforts to enhance clinical engagement and accelerate the impact of digital technology in improving patient care, will be boosted by a new bilateral relationship between two organisations dedicated to...

Read more

The Grants4Apps® Accelerator Berlin 2017

The Grants4Apps® Accelerator is a mentoring program for digital health startups taking place in Berlin. This year's batch with five startups runs from September until November. The program offers mentoring...

Read more

Highland Marketing Recruits Strategy and…

PR and marketing agency Highland Marketing has appointed Lyn Whitfield to the new post of strategy and content director. Whitfield is a journalist by background, who has specialised in writing...

Read more

Philips and PathAI Team Up to Improve Br…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and PathAI, a company that develops artificial intelligence technology for pathology, are collaborating with the aim to develop...

Read more

PatientsLikeMe and Shire Pharmaceuticals…

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

Read more

Biased Bots: Human Prejudices Sneak into…

In debates over the future of artificial intelligence, many experts think of the new systems as coldly logical and objectively rational. But in a new study, researchers have demonstrated how...

Read more

Philips High-Risk Pregnancy Toolkit is …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has been included as a "Developing-World" and "Health" categories finalist in the 'Fast Company - World Changing Ideas...

Read more

Allscripts Announces dbMotionTM Solution…

Allscripts (NASDAQ:MDRX) announced today that its Community interoperability platform, dbMotion Solution, is now available through the cloud via Microsoft Azure. The cloud-based solution offers the same capabilities as the on-premise...

Read more

Health 2.0 Europe 2017

3 - 5 May 2017, Barcelona, Spain. The 8th edition of Health 2.0 Europe will take place in Barcelona in a new location: Fira Montjuic, Plaza España. Health 2.0 Europe will...

Read more

FDA Allows Marketing of First Direct-to-…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC)...

Read more

Public Funding Essential for Advances in…

In the budget President Trump recently submitted to Congress, he asked for a reduction in the 2018 funding of the U.S. National Institutes of Health (NIH) of almost 20 percent...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined